Data after 24 weeks of treatment with bimekizumab in patients with axial spondyloarthritis show good responses overall regardless of prior experience with a tumor necrosis factor inhibitor.
MDedge News
Data after 24 weeks of treatment with bimekizumab in patients with axial spondyloarthritis show good responses overall regardless of prior experience with a tumor necrosis factor inhibitor.
MDedge News
